| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5595830 | The American Journal of the Medical Sciences | 2017 | 19 Pages |
Abstract
Our data clearly demonstrate that ribavirin acts on thyroid cancer cells by inhibiting eIF4E/β-catenin signaling. Our findings suggest that ribavirin has the potential to be repurposed for thyroid cancer treatment and also highlight the therapeutic value of inhibiting eIF4E-β-catenin in thyroid cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Xiawei MD, Yali MD, Zuixuan MD, Xuemei MD, Dan MD, Lin MD, Baolai MD,